IP Library Granted Patent US 9,168,269
Granted Patent B2
US 9,168,269 · App. 13/579,967 · Granted Oct 27, 2015

Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,168,269
App. No.
13/579,967
Granted
Oct 27, 2015
Kind
B2
Abstract

The present invention provides methods and compounds for treating viral infections using modulators of host cell enzymes relating to long chain fatty acid and lipid droplet metabolism. It includes a method of treating viral infections using triacsin C and its relatives, analogs and derivatives as well as other inhibitors of long chain fatty acid metabolism and lipid droplet metabolism.

Claims (8)

1. A method of treating or preventing viral infection in a mammal, comprising administering to the mammalian subject in need thereof a therapeutically effective amount of an agent that inhibits a long chain fatty acid synthesis enzyme, wherein the virus is human cytomegalovirus (HCMV) and the agent is a compound of Formula VIII

wherein R 1 is selected from H, unsubstituted phenyl; substituted phenyl where substitutents are selected from F, Me, Et, Cl, OMe, OCF 3 and CF 3 ; C 1-6 alkyl; and C 3-6 cycloalkyl;

wherein R 3 and R 4 are independently selected from H; C 1-3 alkyl; and phenyl; or R 3 and R 4 taken together form a cycloalkyl of formula —(CH2) n — where n=2, 3, 4 and 5;

wherein R 5 is selected from methyl; CF 3 ; cyclopropyl; unsubstituted phenyl; mono- and disubstituted phenyl where substitutents are selected from F, Me, Et, CN, iPr, Cl, OMe, OPh, OCF 3 , and CF 3 ; unsubstituted heteroaromatic group; and imidazole;

or prodrug thereof, or pharmaceutically acceptable salt or ester of said compound or prodrug thereof.

2. The method of claim 1 , wherein R 5 is

3. The method of claim 1 , wherein the compound of Formula VIII is selected from the group consisting of

4. The method of claim 1 , wherein the virus is HCMV, which further comprises administering a therapeutically effective amount of an agent that inhibits HCMV-encoded DNA polymerase, wherein the agent is selected from the group consisting of gancyclovir, valgancyclovir, cidofovir, and foscarnet.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Oct 29, 2021
From: MACQUARIE US TRADING LLC
To: KADMON CORPORATION, LLC
Reel/Frame 057973/0751 →
TERMINATION OF PATENT AND TRADEMARK SECURITY AGREEMENT Recorded Nov 25, 2019
From: PERCEPTIVE CREDIT OPPORTUNITIES FUND, LP
To: KADMON CORPORATION, LLC
Reel/Frame 051106/0677 →
SECURITY INTEREST Recorded Sep 8, 2015
From: KADMON CORPORATION, LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 036573/0001 →
RELEASE OF SECURITY INTEREST Recorded Sep 1, 2015
From: MACQUARIE US TRADING LLC
To: KADMON CORPORATION, LLC
Reel/Frame 036518/0862 →
SECURITY INTEREST Recorded Aug 31, 2015
From: KADMON CORPORATION, LLC
To: PERCEPTIVE CREDIT OPPORTUNITIES FUND, LP
Reel/Frame 036515/0084 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2013
From: KOYUNCU, EMRE; RABINOWITZ, JOSHUA D.; SHENK, THOMAS
To: THE TRUSTEES OF PRINCETON UNIVERSITY
Reel/Frame 030129/0692 →
CONFIRMATORY LICENSE Recorded Sep 6, 2012
From: PRINCETON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028917/0584 →